05 Sep 2026

CRC Research Update — September 05, 2026

Creator: The CRC Digest
Published: 2026-09-05T11:23:24Z

Today's colorectal cancer research highlights

1 min read

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

CRC Research Update

SCREENING
AI Tool Shows Promise for Scalable Colorectal Cancer Screening
Researchers describe progress toward practical artificial intelligence applications that could expand access to colorectal cancer screening at scale. (Annals of Oncology)
RESEARCH
Multigene Panel Testing Yield Quantified in Colorectal Cancer Patients
A systematic review and meta-analysis examined the diagnostic yield of germline multigene panel testing using next-generation sequencing in unselected patients with colorectal cancer, helping clarify how often inherited genetic factors contribute to diagnosis. (Lancet Gastroenterology & Hepatology)
RESEARCH
KRAS Mutation Enriches Gut Bacteria Linked to Tumor Growth
A study in KRAS-mutant CRC patients and mice found that KRAS reshapes the microbial community, enriching Bacteroides acidifaciens, which predicts poor prognosis and promotes malignant phenotypes in KRAS-mutant tumors. (Cell Host & Microbe)
RESEARCH
Circulating Tumor DNA Predicts Recurrence After Liver Metastasis Resection
A systematic review and meta-analysis found that circulating tumor DNA (ctDNA) serves as a biomarker for recurrence after curative resection of colorectal cancer liver metastases, potentially guiding post-surgical surveillance strategies. (Clinical Colorectal Cancer)
LIVING WITH CRC
Biological Age and Neighborhood Deprivation Linked to Psychological Distress During Chemotherapy
An analysis of 958 adults with stage II-III CRC receiving chemotherapy found that biological age and neighborhood deprivation predict depression and anxiety symptoms, highlighting biosocial factors that may influence mental health during treatment. (Journal of the National Cancer Institute)

🧬 Biomarker Spotlight

Research by genetic subtype — KRAS, BRAF, MSI-H, HER2, and more

Immune Recovery After Surgery Linked to ctDNA Minimal Residual Disease
A prospective study of 1,000 stage II-III CRC patients found that distinct perioperative immunocircadian recovery trajectories were associated with postoperative ctDNA-based minimal residual disease and long-term survival outcomes. (Surgery)

These findings reflect ongoing efforts to personalize surveillance, understand tumor biology, and support quality of life throughout the CRC journey.

Get CRC research intelligence delivered weekly — free.

Browse by Topic

KRAS Mutations Immunotherapy (MSI-H)BRAF Early-Onset / Under 50 Liver Metastases Clinical Trials Living with CRC All Issues

CRC Research Update

Subscribe to The CRC Digest